FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

CDRH Official Clarifies Use of Standards Form in 510(k)

[ Price : $8.95]

CDRH 510(k) team leader Heather Rosecrans clarifies the use of Form 3654 Standards Data Report Form for 510(k)s, which has drawn s...

FDA OKs Novartis Combo Pill for Hypertension

[ Price : $8.95]

FDA approves Novartis Valturna (aliskiren and valsartan) tablets for treating high blood pressure.

FDA to Give Priority Review to Velcade Supplement

[ Price : $8.95]

FDA says it will give priority review to a Millennium sNDA for Velcade to treat patients with previously untreated multiple myelom...

Hamburgs Daunting Mission: Raising Public Respect for FDA

[ Price : $8.95]

FDA Webview editor Jim Dickinson analyzes commissioner Margaret Hamburgs daunting top priority rebuilding public trust and finds...

FDA Accepts ANDAs for Original Zosyn, Approves Orchids

[ Price : $8.95]

FDA approves Orchids ANDA for a generic version of Wyeths original intensive-care antibiotic, Zosyn

Arena Reports Positive Lorcaserin Trial Results

[ Price : $8.95]

Arena says it will submit a December NDA to FDA for its weight management drug lorcaserin.

FDA Testing Benefit/Risk Qualitative Framework

[ Price : $8.95]

CDER operations research analyst Patrick Frey tells an industry audience that a still-developing CDER qualitative framework for be...

Guidance on Allogeneic Pancreatic Islet Products for Diabetes

[ Price : $8.95]

Federal Register Notice: FDA releases a guidance on the types of data and information obtained during IND studies that may be help...

FDA Extends Deadline on Biotechnology Pilot Program

[ Price : $8.95]

Federal Register Notice: FDA extends the deadline for submitting requests to participate in a pilot program on submitting CMC info...

FDA Wants Cityri Risk/Benefit Info

[ Price : $8.95]

FDA asks Sanofi-Aventis for additional risk/benefit information in a Cityri complete response letter.